A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

di de Braud, Filippo, Machiels, Jean-Pascal H., Boggiani, Daniela, Rottey, Sylvie W.H., Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Damian, Silvia, Lapeire, Lore D.F., Tiseo, Marcello, Dermine, Alexandre, Ould-Kaci, Mahmoud, Braunger, Juergen, Rascher, Juliane, Fischer, Daniela, Hoefler, Josef, Mariani, Gabriella L., Cresta, Sara
Pubblicato in Cancers (Basel) (2020)